AI
VNDA icon

Atom Investors’s Vanda Pharmaceuticals VNDA Stock Holding History

Atom Investors’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-193,954
Closed -$2.73M – 440
2019
Q2 		$2.73M Buy
193,954
+183,318
+1,724% +$2.92M 0.18% 156
2019
Q1 		$196K Buy
+10,636
New +$242K 0.02% 484

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Atom Investors's VNDA Position: Q3 2019 in Review

Atom Investors sold out of Vanda Pharmaceuticals (VNDA) in Q3 2019, closing a stake of 193,954 shares — an estimated $2.73M sold.

Atom Investors first reported a position in VNDA in Q1 2019 and held it in 2 quarters. The position peaked at $2.73M in Q2 2019. 168 funds tracked by Wall St. Rank hold VNDA as of Q3 2019.

  • Atom Investors reported no remaining Vanda Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Atom Investors sold 193,954 Vanda Pharmaceuticals shares in Q3 2019, an estimated $2.73M.
  • Atom Investors first reported a position in Vanda Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Atom Investors's Vanda Pharmaceuticals position peaked at $2.73M in Q2 2019.
  • 168 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2019.

Based on Atom Investors's 13F filing for Q3 2019, filed 14 Nov 2019.